Introduction
Two major apoptotic pathways have been delineated for the signaling events leading to activation of effector caspases. The intrinsic/mitochondrial cascade is induced by stress, cytotoxic drugs, irradiation or withdrawal of survival factors. 1 This apoptotic cascade is executed by the release of multiple apoptogenic proteins from the mitochondria to the cytoplasm, including caspases, cytochrome c, apoptosis-inducing factor (AIF), second mitochondria-derived activator of caspase (SMAC/ DIABLO), Omi/HtrA2, and endonuclease G. Whereas AIF and endonuclease G induce caspase-independent nuclear apoptotic events, [2] [3] [4] cytochrome c, SMAC, and Omi/HtrA2 are involved in activation of caspase-3 downstream of the mitochondria. [5] [6] [7] Released cytochrome c forms an apoptotic complex with Apaf-1 and procaspase-9, the apoptosome. 8 Formation of the apoptosome leads to activation of caspase-9, which subsequently activates caspase-3. Mitochondrial-derived SMAC and Omi/ HtrA2 function to promote caspase activation by inhibiting IAP (inhibitors of apoptosis) family members. 4, 9 The extrinsic/death receptor apoptotic cascade is preferentially activated by ligands of death receptors, including Fas ligand, tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL), and TNF-a. 10 The death receptor cascade is executed through recruitment and activation of caspase-8 or caspase-10. 11 Although these two apoptotic pathways can be executed independently, in certain cell types, mitochondrial amplification is required for efficient execution of the death receptor-initiated cascade. 12, 13 The link between the intrinsic and the extrinsic cascades is mediated by Bid, a BH3-only protein, which is cleaved by caspase-8. After being cleaved, the C-terminal fragment of Bid translocates to the mitochondria and induces the release of apoptogenic proteins. 14 It has been demonstrated that the mitochondrial function of truncated Bid (tBid) is dependent on the presence of either Bax or Bak. 15 tBid induces the oligomerization of Bax or Bak into pores that lead to the release of cytochrome c. 16 Cells lacking both Bax and Bak, but not those deficient in only one of these components, are completely resistant to tBid-induced cytochrome c release and apoptosis.
Recent studies have reported that resistance to TRAILmediated apoptosis in a human colon carcinoma cell line is associated with a deficiency in Bax. 17, 18 In these studies, the susceptibility to TRAIL was compared between two HCT116 colon carcinoma cell lines that differ in the Bax locus: a Bax À/À cell line, in which the wild-type allele of a Bax þ /À cell line was inactivated by homologous recombination, and the aforementioned Bax þ /À progenitor cell line itself. 19 The Bax-deficient cells were resistant to TRAIL, whereas the Bax-expressing cells were sensitive. Bax was dispensable for apical death receptor signaling events, including caspase-8 activation, but crucial for mitochondrial changes and downstream caspase activation. 17 Although the Bak gene was expressed and gave rise to a functional Bak protein in these colon carcinoma cell lines, it did not substitute for Bax in mediating the response to TRAIL. These findings suggest that the multidomain proapoptotic Bcl-2 family members, Bax and Bak, may not have complete overlapping functions in all cell types as indicated by studies performed with the Bax/Bak double deficient murine embryonic fibroblasts (MEF). 15, 20 Bax À/À and Bax þ /À HCT116 cell lines also exhibit differential apoptotic susceptibility to an array of cytotoxic drugs, suggesting that Bax or Bak may be distinctively involved in apoptotic cascades initiated by anticancer drugs. 21 In the current study, we utilized a TRAIL-resistant clonal T leukemic cell line that is also deficient in Bax and Bak to directly investigate the roles of ectopicly expressed Bax and Bak in susceptibility to TRAIL-mediated apoptosis. We demonstrate that in T leukemic cells TRAIL preferentially utilizes Bax for induction of mitochondrial apoptotic events. It has recently been proposed that cancer treatment with a combination of TRAIL and anticancer drugs may serve to overcome resistance to TRAIL-mediated apoptosis. It appears that such a combination
RT-PCR, DNA cloning and sequencing
Total RNA was isolated from Jurkat cells using RNA Stat-60 (TelTest 'B', Inc.) following the manufacturer's instructions. Reverse transcription was carried out with 4 mg (J-R) or 5 mg (J-S) of total RNA using oligo (dT) [12] [13] [14] [15] [16] [17] [18] 0 -GCCTCAGCCCATCTTCTT-3 0 (complementary to 3 0 end of Baxa ORF in exon 6). Amplicons were size selected using 1% agarose gels and purified with the QIAquick Gel Extraction Kit (QIAGEN). Plasmid cDNA libraries were generated by subcloning PCR amplicons into the vector pCR3.1 using the Eukaryotic TA Expression Kit (Invitrogen). Automated DNA sequence analysis was carried out on both strands of Bax clones using the forward primer T7 5 0 -TAATACGACTCACTATAGGG-3 0 (corresponds to T7 promoter in pCR3.1) and the BGH reverse primer 5 0 -TAGAAGGCACAGTCGAGG-3 0 (complementary to BGH sequence in pCR3.1) by the University of Pittsburgh DNA Sequencing Core Facility.
Transduction of Jurkat cells by Ad/GT-Bak and Ad/GV16
Construction of Ad/GT-LacZ, Ad/GT-Bak, Ad/GT-Bax and Ad/ GV16 was reported previously. 22, 23 The binary adenoviral vector systems were used to overcome Bax-or Bak-mediated apoptosis in the packaging 293 cell line. In these binary systems, the vectors Ad/GT-Bax or Ad/GT-Bak contain the Bax or Bak genes, respectively, under the control of the GAL4/TATA (GT) promoter and the GAL4/GV16 (GV16) fusion protein. Bax or Bak gene expression could then be induced in target cells by coadministration of the Ad/GT-Bax or Ad/GT-Bak vectors with the second adenoviral vector Ad/GV16, which produces the GAL4/ GV16 fusion protein. The transduction efficiencies of the adenoviral vectors were determined by assessing the titer needed to infect the cells with Ad/GT-LacZ and Ad/GV16.
Western blot analysis
To generate whole-cell extracts, cells were lysed in 0.5% NP-40, 10 mM HEPES pH 7.4, 142 mM KCl, 5 mM MgCl 2 , 1 mM EGTA, 1 mM PMSF, 10 mg/ml leupeptin and 10 mg/ml aprotinin. Proteins were resolved by SDS/PAGE and transferred onto PVDF membranes, as previously described. 24 Following probing with a specific primary Ab and horseradish peroxidaseconjugated secondary Ab, the protein bands were detected by enhanced chemiluminescence (Pierce, Rockford, IL, USA).
Subcellular fractionation
To obtain mitochondria and S-100 cytosol fractions, Jurkat cells were suspended in mitochondria buffer (MIB) composed of 0.3 M sucrose, 10 mM MOPS, 1 mM EDTA and 4 mM KH 2 PO 4 pH 7.4 and lysed by Dounce homogenization as previously described. 24 Briefly, nuclei and debris were removed by 10 min centrifugation at 650 g and a pellet containing mitochondria was obtained by two successive spins at 10 000 g for 12 min. To obtain the S-100 fraction, the postnuclear supernatant was further centrifuged at 100 000 g for 1 h at 41C.
Results

Baxa deficiency in wild-type Jurkat cells
Multiple studies have reported the expression of Bax in Jurkat cells based on recognition by commercial antibodies. [25] [26] [27] [28] However, other studies have reported that similar to colon carcinoma various hematopoietic tumors, including Jurkat cells, can display sequence instability at genomic microsatellite sites because of a deficiency in mismatch repair (MMR). This deficiency can result in altered mononucleotide tracts throughout the genome, and thus can affect the sequence integrity of the Bax gene. [29] [30] [31] The Bax gene contains a (G) 8 tract in exon 3 (nt 114-121; Figure 1a ) that spans codons 38 through 41 (ATG GGG GGG GAG) and therefore is located 21 codons upstream of the BH3 domain present in Bcl-2 family members. The (G) 8 tract is often mutated in one or both Bax gene alleles by the addition (G) 9 and/or deletion (G) 7 of a single G nucleotide when the microsatellite mutator phenotype is present. Thus, the insertion or deletion of a single G nucleotide would shift the Bax reading frame beginning with codon 41 GAG (Glu) to GGA (Gly) or AGG (Arg), respectively. Both mutated reading frames would also generate prematurely terminated Bax translation products (B7.3 kDa (G) 9 ; B6.4 kDa (G) 7 ) that lack the BH3, BH1, BH2 and TM domains (Figure 1a) . To determine the status of the Bax gene(s) exon 3 (G) 8 tract in wild-type Jurkat cells, we generated a Bax cDNA library utilizing RT-PCR with a primer pair specific for the 5 0 terminus of exon 3 and the 3 0 terminus of the Baxa ORF in exon 6 ( Figure 1a ; Materials and methods). In total, 19 randomly picked colonies were sequenced: 15 had single G deletions (G) 7 and 4 had single G insertions (G) 9 . Similar results involving 14 cDNA clones (13 (G) 7 ; one (G) 9 ) were obtained with an additional Bax cDNA library constructed as above, but utilizing RNA from a TRAIL-resistant Jurkat cell line (J-R, see below). The detection in our Jurkat cells of both the single G insertion and deletion alleles is in agreement with other reports about the Jurkat Bax gene. 29, 30 These findings suggest that Bax mRNA splice variants in Jurkat cells that contain exon 3, including Bax-a, b, -e, -s, and -o, will not be functional because of a translational frameshift starting with codon 41 that results in premature termination. Our DNA sequence analysis was corroborated by an immunoblot of Jurkat cell lysates, control and a lysate from cells that were transfected with the Baxa gene using the Ad/GT-Bax binary vector expression system (Figure 1b; Materials and methods). It is readily apparent that the control cell lysate does not exhibit a band that corresponds with the Baxa band displayed by the viral transduced cell lysate. Our analysis of the Bax cDNA sequence was performed with Jurkat cells obtained from ATCC just prior to the study. Thus, the apparent lack of the wild-type Bax gene characterizes the source cells and does not represent an alteration acquired during cell passages. These results suggest that the Jurkat cells obtained from the ATCC as well as their derivative clonal cell lines are deficient in Bax isotypes that are encoded by splice variant mRNAs that contain exon 3, including Bax-a, -b, -e, -s, and -o proteins.
Characterization of J-R clonal cell line
The Jurkat cell line used in these studies was initially selected for resistance to Fas-mediated apoptosis. Following limiting dilution analysis, 15 clonal cell lines resistant to Fas-mediated apoptosis were obtained. The clonal cell line used in this study (clone #4) was found to carry a deficiency in the Bak protein. This deficiency was confirmed by immunoblotting with a total of seven different anti-Bak Abs generated against various immunogens ( Figure 1c , results for 3 anti-Bak Abs are presented). Thus, wild-type Jurkat cells express Bak, but not Baxa, whereas the J-R clonal cell line possesses a double-deficiency in both Baxa and Bak. In addition to the resistance to Fas-mediated apoptosis, the Bax/Bak-deficient Jurkat cells demonstrated resistance to cisplatin and VP-16 ( Figure 1d ). However, these J-R cells were as sensitive as wild-type Jurkat cells to paclitaxel, lonidamine or betulinic acid. These cytotoxic drugs have been reported to have direct effects on mitochondria [32] [33] [34] that result in cytochrome c release following treatment of either cells or purified mitochondria. 32, 35 The intrinsic apoptotic cascades induced by these drugs are at least partially independent of Bax and Bak. Other Fas-resistant and Bak-deficient Jurkat clones that we have identified 36 exhibit similar apoptotic susceptibility to that of the J-R clonal cell line.
Resistance of Bax/Bak-deficient J-R cells to TRAIL-mediated cell death
Treatment of J-R clonal cells with various doses of TRAIL (50-1000 ng/ml) for different time periods (up to 72 h) had no effect on the cell survival as assessed by staining with an exclusion dye, annexin V (Figure 2a ) or proliferation capability (data not shown). However, in contrast to Fas crosslinking, where no transduction of an apoptotic signal was noted, treatment of J-R cells with TRAIL induced the processing of caspase-3 to its p20 subunit (Figure 2b, c) . Previous studies have shown that processing of caspase-3 involves an initial cleavage generating the p12 small subunit and the p20 partially processed large subunit. p20 is further processed by autocatalytic removal of its N-terminal prodomain to generate p19 and p17 polypeptides. 7, 37 The p20 caspase-3 generated in response to TRAIL appears to be inhibited, as it did not further process itself (Figure 2b ) or other substrates such as Poly(ADP-ribose) polymerase (PARP, Figure 2e) . In wild-type Jurkat cells, partial processing of the p20 was detected with a relatively low dose of TRAIL (100 ng/ml), whereas full processing was seen with an increased TRAIL dose (200 ng/ml) (Figure 2b ). Stable transfection of either CrmA or Bcl-2 into wild-type Jurkat cells partially inhibited the processing of prodomain caspase-3 as well as the processing of p20 (Figure 2d ). These observations are consistent with the ability of CrmA to inhibit caspase-8-mediated processing of caspase-3, and that of Bcl-2 to inhibit the mitochondrial contribution to caspase-3 processing. TRAIL-mediated processing of caspase-3 into its p20 subunit in J-R cells is mediated by caspase activity, as it was inhibited in the presence of either Z-VAD-FMK, a pan-caspase peptide inhibitor, or by Z-IETD-FMK, a peptide inhibitor that targets caspase-8, but is not entirely selective for caspase-8. However, in contrast to wild-type Jurkat cells, in J-R cells we did not detect activity of caspase-8, -10, -7, or -2 as assessed by reduced prodomain expression following TRAIL stimulation (Figure 2e) . Currently, it is not clear which caspase activity is responsible for the caspase-3 cleavage in J-R cells in response to TRAIL. It may be a yet unknown caspase that is active upstream of caspase-3, or may be mediated by the activity of caspase-8 or -10 that does exhibit a significantly altered expression level for the prodomain, as assessed by immunoblotting. Indeed, a dimerization mechanism for activation of apical caspases (caspase-8, -9 and -10) has recently been elucidated. 38, 39 According to a recently proposed unified model, dimerization may override the need for caspase cleavage, as activation of uncleavable caspase-8 was observed upon its dimerization. 39 Such caspase-10 activity (that is detectable only by colorimetric assay and by pancaspase inhibition) may be responsible for the cleavage of caspase-3 and low-level processing of Bid in TRAIL-treated J-R cells (Figure 2e ). Bid has been reported to be a substrate for various proteases, including caspases, granzyme B, and papain-like lysosomal cathepsins. 40 Thus, Bid cleavage in TRAIL-treated J-R cells could have been mediated by noncaspase proteases that are activated upon TRAIL stimulation. However, the detected tBid did not function to release mitochondrial apoptogenic proteins, as treatment of J-R with TRAIL was not associated with the detection of cytochrome c or AIF in the cytosolic S-100 fraction of these cells (Figure 2f ).
Restoration of TRAIL susceptibility following Bax gene transduction into J-R cells
Using binary adenoviral vector systems we successfully produced large amounts of Ad/GT-Bax and Ad/GT-Bak, whose gene products (Bax or Bak) were under the transcriptional control of the GT promoter and GAL4/GV16 fusion protein. 22, 23 To induce the expression of Bax, J-R cells were transduced with Ad/GTBax þ Ad/GV16, whereas for Bak, the cells were transduced with Ad/GT-Bak þ Ad/GV16. The binary adenoviral LacZ vector system (Ad/GT-LacZ þ Ad/GV16) was used to determine transduction efficiency. We used these binary adenoviral vector systems to investigate the involvement of Bax or Bak in TRAILmediated apoptosis of J-R cells (Figures 3 and 4) . Since J-R cells are TRAIL-resistant, and deficient in Bax and Bak, ectopic expression of each of these proteins is expected to determine their relative contribution to the execution of a mitochondrial cascade in response to TRAIL. Overexpression of Bax or Bak has been reported to induce cell death. 22, 41 To reduce the level of Bax-mediated cell death, we performed Bax gene transduction with a fixed dose of the Ad/GV16 vector and a series of escalating doses of the Ad/GT-Bax vector (Figure 3a) . The various doses of Bax gene transduction into J-R cells were associated with a relatively low range of cell death (25-52%), which was significantly increased in the presence of TRAIL (55-85%). In these experiments, cell death was assessed by flow cytometry of cells stained with annexin V/propidium iodide and also by % survival of cells stained with an exclusion dye. Either assessment indicated an increased susceptibility to TRAIL mediated by Bax. Since an assessment by flow cytometry, using annexin V staining provides only a snap-shot of current apoptotic cells, but does not take into account the cumulative cell loss throughout the treatment period, we present in Figures  3 and 4 the cumulative cell loss that measures the true proportion of the affected cells during the 12 h treatment. Treatment with TRAIL alone (at various doses) did not lead to cell death above the control background (5-7% cell death), and was associated with the generation of caspase-3 p20 that was not further processed. In contrast to treatment with TRAIL, Bax gene transduction induced the processing of caspase-3 into p19 and p17. However, in cells transfected with Bax, TRAILmediated a significantly increased processing of the caspase-3 prodomain zymogen (p32) in a Bax-dependent manner. As compared to the effects of TRAIL alone or Bax gene transduction alone, treatment of Bax-transduced cells with TRAIL also enhanced the degradation of caspase-3 substrates, PARP and of XIAP (Figure 3a) . Thus, the ability of Bax to mediate TRAIL Figure 3 Restoration of susceptibility to TRAIL in J-R cells transduced with the Bax gene. J-R cells were transduced with a combination of two adenoviral vectors composing the binary system for transduction and expression of the Bax gene (described in Materials and methods). Ad/GV16 was applied at a fixed dose together with a series of ascending doses of Ad/GT-Bax vector (Bax transduction). At 2 h after the application of the adenoviral vectors, the cells were treated with two doses of TRAIL (100 ng/ml (1) and 400 ng/ml (2) susceptibility to J-R cells is evidenced by the marked increase in cumulative cell loss, the decrease in expression of caspase-3 prodomain (p32), and the increased degradation of PARP and XIAP. A slight decrease in expression of transduced Bax was noted in cells presenting a high level of apoptosis (Figure 3a ). This decrease was inhibited when Bax transduction was performed in the presence of Z-VAD-FMK (data not shown), suggesting that the expression of Bax is modulated in cells with high caspase activity. No changes in the levels of cell death or caspase-3 processing were detected in J-R cells treated with adenoviral vector controls (Figure 3b) .
Similar to Bax, Bak gene transduction performed in a similar manner to that of Bax also induced apoptotic death in J-R cells (Figure 4) . However, as assessed by percent cell loss, the presence of Bak did not facilitate TRAIL activity in these cells. Transduction of Bak induced the processing of caspase-3, so that both p20, p19 and p17 were detected (Figure 4, top) . However, treatment with TRAIL of Bak-transduced cells (Figure 4, top) did not result in a significant loss of caspase-3 prodomain (p32) as detected in Bax-transduced cells (Figure 3a, top) . Likewise, similar levels of PARP processing and XIAP expression were detected in J-R cells when transduced with Bak or when transduced with Bak and subsequently treated with TRAIL. The transduction experiments for Bax and Bak were conducted with several doses of TRAIL ranging from 100 to 400 ng/ml. As Bax transduction mediated susceptibility to TRAIL, and similar results were obtained with increased doses of TRAIL, the results obtained with the minimal dose of TRAIL applied together with Bax (TRAIL (1), 100 mg/ml) are presented in Figure 3 . However, Bak transduction did not sensitize the cells to TRAIL. To demonstrate that the sensitivity was not dependent on the dose of TRAIL, the results obtained with the highest dose of TRAIL applied together with Bak (TRAIL (2), 400 ng/ml) are shown in Figure 4 . Noteworthy, wild-type Jurkat cells are TRAIL-sensitive despite a Bax-deficiency (and Bak expression), as in these cells the mitochondria-independent death receptor cascade was functional. The J-R cells were of value in determining the roles of Bax and Bak in response to TRAIL, since in these cells the death receptor pathway was not operative and response to TRAIL was entirely mitochondria-dependent.
Discussion
Recombinant TRAIL has been considered a promising treatment for cancer as this death receptor ligand preferentially induces apoptosis in tumor cells and not in normal cells. 42, 43 It has also exhibited potent antitumor activity in xenograft animal models of colon, 44 breast, 45 and glial tumors. 46 Initial studies on TRAILmediated cell death suggested that in lymphoid cells overexpression of Bcl-2 did not confer protection against TRAILmediated apoptosis. 47, 48 These studies suggested that TRAILmediated apoptosis is executed through a caspase cascade, independent of the mitochondria, and therefore, this type of therapy might be suitable for tumor cells resistant to chemotherapy. However, recent studies have demonstrated that TRAIL is not effective in certain tumor types with increased expression of Bcl-2 or XIAP. 49 The different patterns of mitochondriadependent and mitochondria-independent apoptotic cascades mediated by TRAIL may be explained by the potential existence of two cell type-specific death receptor signaling pathways, as proposed by Scaffidi et al. 50 The difference between these two cell types has been ascribed to the efficiency of DISC formation. In those cell types with optimal DISC formation (Type I), a direct caspase cascade is initiated independently of the mitochondria. Cells with inefficient DISC formation (Type II) require mitochondria amplification for the extrinsic pathway. It has been recently proposed that Type II cells are featured by overexpression of IAP family members that block caspase activity. 13 Mitochondrial contribution in such cells may be manifested by the release of IAP inhibitors, like SMAC and HtrA2, that relieve caspase-3 and -9 of the IAP inhibition. 51, 52 These recent findings suggest that in cancer cells, classified as Type II, resistance to TRAIL may be mediated by the abrogation of mitochondrial apoptotic events. In support of this possibility, it has been reported that overexpression of Bcl-2 conferred protection against TRAIL in neuroblastoma, glioblastoma, and breast carcinoma cell lines. 49 Studies performed with MEF deficient in both Bax and Bak demonstrated that these proapoptotic proteins are functionally overlapping, as the presence of either one was essential for apoptosis induced by multiple stimuli. 15, 20 However, the concept of complete redundancy between Bax and Bak has Bak gene transduction does not restore TRAIL susceptibility to J-R cells. Experimental details are similar to those described for Bax in Figure 3 .
Bax and Bak in TRAIL-mediated apoptosis J Han et al recently been challenged, as HCT116 colon carcinoma cells deficient in Bax, but not in Bak, were found to be TRAILresistant. 17, 18 Bax À/À HCT116 cells that express functional Bak, were deficient in apoptosis mediated by multiple stimuli, including UV, staurosporin, and thapsigargin that induce either mitochondrial or endoplasmic reticulum stress. 21 Furthermore, recent studies suggest that the Bax and Bak proteins are differentially regulated. Thus, the antiapoptotic Bcl-B protein binds Bax and suppresses its apoptotic capability, but does not bind or have any inhibitory effect on Bak. 53 Conversely, mitochondrial VDAC2 serves as a suppressor of Bak-mediated apoptotic events, but does not affect Bax function. 54 These studies indicate that Bax and Bak may not have fully overlapping functions in all cell types and in response to various apoptotic agents.
In the current study, we have taken a direct approach to examine the roles of Bax and Bak in TRAIL-mediated apoptosis. This direct approach was enabled by the identification of a clonal Jurkat cell line where an apoptotic response to TRAIL is completely dependent on the mitochondrial cascade. This clonal cell line was obtained from a polyclonal cell line resistant to Fas. In contrast to Fas signal transduction, which appears to be blocked upstream of caspase-8, TRAIL signaling in these cells proceeds in a caspase-dependent manner up to the processing of caspase-3 to its p20 subunit. Yet, the exact nature of the caspase activity in J-R cells treated with TRAIL that is responsible for the processing of caspase-3 has not yet been resolved. A caspase-8-independent component in TRAIL-induced apoptosis in human rhabdomyosarcoma cells has recently been documented. 55 In those cells, dominant-negative caspase-8 only partially inhibited TRAIL-induced apoptosis, but did not inhibit the cleavage of Bid or the activity of Bax. 55 Likewise, caspase-3 processing observed in J-R cells may be mediated by a yet unknown caspase, or by activity of caspase-8 or -10, that are undetectable by immunoblotting of the prodomain. 38, 39 The activity of caspase-3 p20 in these TRAILtreated cells appears to be blocked as no DEVDase activity or further auto-processing or cleavage of caspase-3 substrates were detected. The actual mechanism for p20 inhibition in these cells is not known. It might be mediated by an IAP family member, as is the case in XIAP overexpressing cells, where caspase-3 processing is blocked at the p20 level. 13, 56, 57 Since XIAP is similarly expressed in J-S and J-R cells, the block in the TRAIL mitochondrial cascade is likely to be mediated by an IAP-like protein rather than by XIAP itself. It has recently been reported that SMAC released from the mitochondria can bind XIAP and thus relieve caspase-3 inhibition. 7, 51, 52 Furthermore, the first 4-8 N-terminal amino acids of Smac/DIABLO fused to various carrier peptides, penetrate the cell membrane and enhance the induction of apoptosis in response to diverse antineoplastic agents. 58, 59 However, co-treatment of J-R cells with TRAIL and such a SMAC agonistic peptide (4-7 N-terminal amino acids of Smac/DIABLO) did not enhance the susceptibility of J-R to TRAIL (our unpublished data). These findings further suggest that the block in caspase-3 p20 processing in J-R cells is not mediated by XIAP itself. However, the presence of exogenous cytochrome c allowed the autoprocessing of endogenous p20 caspase-3 to proceed (data not shown), suggesting that an impaired release of mitochondrial apoptogenic proteins is associated with the block in caspase-3 processing. Mitochondria from Bax/Bak deficient cells, either MEF or Jurkat T cells, are defective in their cytochrome c releasing capability. Through adenoviral vector transduction of either Bax or Bak, we investigated the roles of these proapoptotic proteins in the facilitation of the TRAIL response. Although overexpression of either Bax or Bak was associated with induction of cell death and a relatively low level of caspase-3 processing, only Bax transfection restored TRAIL susceptibility to these resistant cells. The observed distinct roles of Bax and Bak in TRAIL-mediated apoptosis may suggest that these proapoptotic proteins carry differential capabilities for releasing mitochondrial apoptogenic proteins. Such differences may be quantitative, relating to the efficiency of Bax or Bak in the liberation of mitochondrial proteins, or qualitative, relating to a potential selective gating of specific proteins by Bax or Bak. Currently, the exact mechanisms responsible for the release of various mitochondrial proteins are not clear. An important question that remains unsolved is whether the channel responsible for mediating the release of cytochrome c (B12 kDa) is large enough to accommodate larger proteins, including AIF (B67 kDa), caspase-9 (B46 kDa), HtrA2 (B38 kDa) or SMAC (B25 kDa that behaves as a B100 kDa protein when it is released as a dimer complex 60 ). It is also not known if the same mitochondrial mechanism (channel?) responsible for the release of cytochrome c is also responsible for the release of other mitochondrial intermembrane apoptogenic proteins. Furthermore, the effect of the loss in expression of either Bax or Bak, structural components of such channels, on the conductivity of the channels remains unknown.
It is possible that the differential roles of Bax and Bak in the TRAIL apoptotic response relate not only to their unique capability of releasing mitochondrial intermembrane apoptotic proteins, but also to the different subcellular localization of these Bcl-2 family members. Whereas Bak is a mitochondrial protein, Bax resides mainly in the cytoplasm and translocates to the mitochondria upon apoptotic stimulation. Thus, Bax may respond to the cytosolic stimulation via TRAIL, translocate to the mitochondria and trigger a mitochondrial apoptotic cascade, which proceeds independently of Bak expression. In contrast, in the absence of Bax, particularly when coupled with inefficient Bid cleavage, a linkage between TRAIL cytosolic stimulation and mitochondrial Bak may be missing. However, a preferential role for Bax over Bak in response to TRAIL has also been noted in Bax À/À HCT116 in association with an efficient Bid cleavage. 17 The presence of functional Bak in these cells also could not substitute for Bax in response to the nonsteroidal antiinflammatory drugs (NSAIDs), sulindac sulfite and doxorubicin, suggesting that various anticancer drugs may preferentially utilize either Bax or Bak. 19 Bax À/À HCT116 cells were sensitized to TRAIL by pretreatment with VP-16. 17 VP-16-mediated upregulation of Bak expression has been considered as the mechanism for this sensitization. However, it is possible that in contrast to TRAIL, VP-16 has the capability of utilizing mitochondrial Bak to induce the release of mitochondrial proteins, such as SMAC and HtrA2, required for the relief of caspase-3 inhibition by IAPs. Once the mitochondrial contribution is enabled through VP-16 stimulation it generates the conditions required for the TRAIL-initiated cascade to proceed. Such a scenario would suggest that the treatment of Baxdeficient tumor cells with TRAIL would have to be combined with chemotherapeutic agents that are Bax-independent, but can efficiently utilize Bak.
In summary, the current study provides direct evidence for the preferential usage of Bax over Bak in TRAIL-mediated apoptosis of T leukemic cells. The preferential usage of Bax has also been indicated in colon carcinoma cells suggesting that this preference is stimulation-specific rather than cell-type specific. Further studies are required to determine whether Bax and Bak are preferentially involved in the apoptotic response of various tumors to anticancer drugs.
